Evaluation of coagulation factor concentrates for persistent bleeding after cardiothoracic surgery

Clicks: 12
ID: 332226
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #237 of 247 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Purpose The purpose of this study was to evaluate the effectiveness and safety of changes to a protocol for refractory bleeding after cardiothoracic surgery. The protocol changes included adjusting from a weight-based to a fixed-dosing strategy for 4-factor prothrombin complex concentrate (4F-PCC) and decreasing the weight-based dosing of recombinant activated factor VII (rFVIIa). Methods This was a pre-post retrospective cohort study evaluating 198 adult patients after cardiothoracic surgery requiring cardiopulmonary bypass at an academic medical center between May 2019 to October 2021 (before protocol change) and November 2021 to September 2022 (after protocol change). The primary outcome was chest tube output at 24 hours after the operation in patients who received at least one dose of 4F-PCC or rFVIIa. Secondary endpoints included transfusion volume, the rate of re-exploration events, length of stay, and 30-day mortality. Results The primary outcome of chest tube output at 24 hours was 720 mL in the pre-change group and 700 mL in the post-change group (P = 0.982). The volume of fresh frozen plasma (FFP) transfusions significantly decreased from a median of 4 units to 2 units (P < 0.001). The median dose of 4F-PCC in the pre- vs post-change group was 24.6 vs 26.3 units/kg (P = 0.011), while that of rFVIIa was 59.5 vs 24.5 μg/kg (P = 0.000). The other secondary and safety outcomes were similar between the groups. The average cost savings was $3,585.45 per patient. Conclusion Patients in the post-change group had similar chest tube output, re-exploration rates, and incidence of thrombotic events. The post-change group received significantly less FFP and less coagulation factor concentrate while maintaining hemostasis and reducing cost.
Reference Key
openalex_W7221598161 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Maria F Hartwig, RaeAnn Hirschy, Jordan Meckel
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag339
URL
https://doi.org/10.1093/ajhp/zxag339
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.